4Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods :report from the ARTEMIS Global Antifungal Susceptibility Program, 2001 [ J ]. J Clin Microbiol, 2003,41 : 1440.
5Seibold M, Tintelnot K. Susceptibility testing of fungi-current status and open questions[J]. Prog Drug Res,2003,9:191.
6Hazen KC, Baron E J, Colombo AL, et al. Comparison of the Susceptibilities of Candida spp. To Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion[J] .J Clin Microbiol,2003,41:5623.
4Denning DW,Munoz P. Advances in invasive fungal infection and antifungal terapy : Introduction. Clin Microbiol Infect ,2001,7 Suppl 2:6.
5Ely EW, Peacock JE Jr, Haponik EF, et al. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore), 1998, 77:153-167.
6Bechsague C. Trends in epidemiology of nosocomial fungal infection in the United States section in acute leukemia. Chin Microbiol Infect, 1994, 8:363.
7Mitctll TG, erfect JR. Cryptocococcosis in the era of AIDS100 years after the discovery of Cryptococcus neofomans. Clin Microbiol, 1995, 8:515.
8MIUSHIMAY, LI H, YOSHIDA I, et al. Changes in ehinical features of fungemia in a Japanese University Hospital a 12-year period[ J ]. Intern Med, 1996,36:707-771.
9st-GERMAIN G, LARERDIERE M, PELLETIER R, et al . Prevaence and antifungal susceptibility of 442 candida isolaesfrom blood and other normally sterili sites: yesults of a 2-year ( 1996 to 1998) muhlcenter sayveillance study in Quebec Canada [ J ]. J Clln Microbiol, 2001,39:949-953.
10ABBAS J,BODEY G P,HANNA H A,et al. Candida Krusei fungenua Anescalating serious ifeclion in immunompromised patients [ J ]. Arch Intenl Med ,2000,160:2659-2661.
4Pfaller MA,Diekema DJ,Messer SA,et al.Activities of fluconazole and voriconazole against 1 586 recent clinical isolates of Candida species determined by Broth microdilution,disk diffusion,and Etest methods:report from the ARTEMIS Global Antifungal Susceptibility Program[J].J Clin Microbiol,2003,41:1440-1446.
5Seibold M,Tintelnot K.Susceptibility testing of fungi-current status and open questions[J].Prog Drug Res,2003,9:191-241.
6Hazen KC,Baron EJ,Colombo AL,et al.Comparison of the Susceptibilities of Candida spp.To Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion[J].J Clin Microbiol,2003,41:5623-5632.
7Sorrell TC, Chen SC, Ruma P, et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting [ J ]. J Clin Microbiol, 1996,34 ( 5 ) : 1253 - 1260.
8Khosravi AR. Isolation of Cryptococcus neoformans from pigeon ( Columba livia) droppings in northern Iran[J]. Mycopathologia, 1997,139(2) :93 -95.
9Castan6n-Olivares LR, L6pez-Martfnez R. Isolation of Cryptococcus neoformans from pigeon (Columbalivia) droppings in Mexico city[ J]. Mycoses,1994,37(9-10) :325 -327.
10Refai M, Taha M, Selim SA, et al. Isolation of Cryptococcus neoformans, Candida albicans and other yeasts from pigeon droppings in Egypt[J]. Sabourandia, 1983,21 ( 2 ) : 163 - 165.
